New drug tested for Tough-to-Treat breast cancer
NCT ID NCT04829604
Summary
This study is testing an experimental drug called ARX788 for people with advanced HER2-positive breast cancer that has spread and has stopped responding to a previous targeted therapy. About 72 participants will receive ARX788 through an IV every three weeks to see if it can shrink tumors and control the disease. The main goal is to measure how many patients see their tumors get significantly smaller.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Los Angeles, California, 90033, United States
-
Research Site
Newport Beach, California, 92663, United States
-
Research Site
San Francisco, California, 94158, United States
-
Research Site
Whittier, California, 90602, United States
-
Research Site
Atlanta, Georgia, 30322, United States
-
Research Site
Chicago, Illinois, 60611, United States
-
Research Site
Louisville, Kentucky, 40207, United States
-
Research Site
Silver Spring, Maryland, 20904, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
St Louis, Missouri, 63110, United States
-
Research Site
Omaha, Nebraska, 68130, United States
-
Research Site
Las Vegas, Nevada, 89128, United States
-
Research Site
Camden, New Jersey, 08103, United States
-
Research Site
New Hyde Park, New York, 11042, United States
-
Research Site
New York, New York, 10028, United States
-
Research Site
Shirley, New York, 11967, United States
-
Research Site
The Bronx, New York, 10469, United States
-
Research Site
Portland, Oregon, 97213, United States
-
Research Site
Tigard, Oregon, 97223, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Dallas, Texas, 75246, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
San Antonio, Texas, 78229, United States
-
Research Site
Norfolk, Virginia, 23502, United States
-
Research Site
Tacoma, Washington, 98405, United States
-
Research Site
Frankston, Victoria, 3199, Australia
-
Research Site
Geelong, Victoria, 3220, Australia
-
Research Site
Nedlands, Western Australia, 6009, Australia
-
Research Site
Daegu, 42601, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 02841, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
Conditions
Explore the condition pages connected to this study.